Influenzanet is a system to monitor the activity of influenza-like-illness (ILI) with the aid of volunteers via the internet

http://www.influenzanet.eu/

Epiwork Logo
Developing the framework for an epidemic forecast infrastructure.
http://www.epiwork.eu/

The Seventh Framework Programme (FP7) bundles all research-related EU initiatives.

7th Framework Logo
Participating countries and volunteers:

The Netherlands 12261
Belgium 3995
Portugal 2149
Italy 0
Great Britain 3342
Sweden 8763
Austria 559
Switzerland 162
France 0
Spain 1012
Ireland 351
Denmark 2917
InfluenzaNet is a system to monitor the activity of influenza-like-illness (ILI) with the aid of volunteers via the internet. It has been operational in The Netherlands and Belgium (2003-2017), Portugal (since 2005) and Italy (since 2008), and the current objective is to implement InfluenzaNet in more European countries.

In contrast with the traditional system of sentinel networks of mainly primary care physicians coordinated by the European Influenza Surveillance Scheme (EISS), InfluenzaNet obtains its data directly from the population. This creates a fast and flexible monitoring system whose uniformity allows for direct comparison of ILI rates between countries.

Any resident of a country where InfluenzaNet is implemented can participate by completing an online application form, which contains various medical, geographic and behavioural questions. Participants are reminded weekly to report any symptoms they have experienced since their last visit. The incidence of ILI is determined on the basis of a uniform case definition.

Hide this information

New hi-tech survey accelerates collection of vaccination data

New hi-tech survey accelerates collection of vaccination data

New technology now makes it possible to collect 'near real-time' data about whether people are having any side effects from vaccination. By studying people who received the 2009-10 swine flu vaccination in Scotland, researchers showed that this rapid reporting can add another layer of safety to future vaccination campaigns.

In addition, the data collected revealed no significant safety issues in patients exposed to the vaccine. The project's report has just been published in the British Journal of Clinical Pharmacology. CONTINUE READING

Nov. 15, 2011, midnight